Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21606214 | 0.80 | NOS1 (0.31) | NOS1 | |
| SCHEMBL26854575 | 0.80 | NOS1 (0.31) | NOS1 | |
| SCHEMBL26854574 | 0.80 | NOS1 (0.31) | NOS1 | |
| SCHEMBL2362852 | 0.76 | — | — | |
| SCHEMBL10568094 | 0.75 | KCNH2 (0.37) | — | |
| SCHEMBL7063305 | 0.75 | — | — | |
| SCHEMBL2652895 | 0.74 | TSHR (0.31) | NOS1 | |
| SCHEMBL174399 | 0.74 | — | — | |
| SCHEMBL5713342 | 0.74 | NOS1 (0.34) | MEN1KMT2ANOS1 | |
| SCHEMBL10566838 | 0.73 | CYP19A1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182467-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2024-06-06 | — | — | US | disclosed |
| US-11814384-B2 | Inhibtors of Raf kinases | KINNATE BIOPHARMA INC. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-3953347-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2022-02-16 | — | — | EP | disclosed |
| WO-2020207414-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020164993-A1 | PESTICIDALLY ACTIVE PYRAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020164994-A1 | PESTICIDALLY ACTIVE PYRAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182467-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | MEN1 2171/4885KMT2A 1631/4885NOS1 4572/4885 |
| US-11814384-B2 | Inhibtors of Raf kinases | RAF1, BRAF, ARAF | MEN1 2203/4885KMT2A 2824/4885NOS1 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.